Lineage Cell Therapeutics, Inc. (NYSEAMERICAN:LCTX – Get Free Report) Director Michael Mulroy purchased 30,000 shares of the company’s stock in a transaction on Tuesday, November 17th. The stock was purchased at an average price of $0.87 per share, for a total transaction of $26,100.00. Following the purchase, the director directly owned 328,555 shares of the company’s stock, valued at $285,842.85. This trade represents a 10.05% increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink.
Lineage Cell Therapeutics Stock Performance
Shares of LCTX traded down $0.02 during mid-day trading on Thursday, reaching $0.82. 1,310,485 shares of the company’s stock traded hands, compared to its average volume of 1,367,679. The business’s 50-day moving average price is $0.98 and its 200-day moving average price is $1.29. The stock has a market capitalization of $207.43 million, a P/E ratio of -9.11 and a beta of 1.68. Lineage Cell Therapeutics, Inc. has a 12 month low of $0.77 and a 12 month high of $1.99.
Lineage Cell Therapeutics (NYSEAMERICAN:LCTX – Get Free Report) last issued its quarterly earnings data on Thursday, November 12th. The company reported ($0.03) earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of ($0.03). Lineage Cell Therapeutics had a return on equity of 3.16% and a net margin of 16.18%. The business had revenue of $1.43 million during the quarter, compared to analyst estimates of $2.32 million. Equities research analysts anticipate that Lineage Cell Therapeutics, Inc. will post -0.04 EPS for the current year.
Analyst Ratings Changes
Separately, Raymond James Financial reissued a “market perform” rating on shares of Lineage Cell Therapeutics in a report on Friday, November 13th. Four investment analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company. According to data from MarketBeat, Lineage Cell Therapeutics has an average rating of “Moderate Buy” and a consensus target price of $6.25.
Read Our Latest Stock Report on LCTX
Institutional Inflows and Outflows
Several institutional investors and hedge funds have recently made changes to their positions in the stock. BlackRock Inc. bought a new position in Lineage Cell Therapeutics during the 2nd quarter valued at $17,275,000. Defender Capital LLC. lifted its holdings in shares of Lineage Cell Therapeutics by 0.8% in the third quarter. Defender Capital LLC. now owns 6,648,899 shares of the company’s stock valued at $6,354,000 after buying an additional 50,000 shares during the period. Raffles Associates LP bought a new position in Lineage Cell Therapeutics during the second quarter valued at about $6,809,000. Fifth Third Bancorp boosted its stake in Lineage Cell Therapeutics by 6.5% during the third quarter. Fifth Third Bancorp now owns 4,900,000 shares of the company’s stock valued at $4,683,000 after buying an additional 300,000 shares in the last quarter. Finally, Goldman Sachs Group Inc. grew its holdings in Lineage Cell Therapeutics by 24.2% during the third quarter. Goldman Sachs Group Inc. now owns 537,965 shares of the company’s stock worth $514,000 after acquiring an additional 104,699 shares during the period. 62.47% of the stock is currently owned by institutional investors.
Lineage Cell Therapeutics Company Profile
Lineage Cell Therapeutics is a biotechnology company developing cell-based therapies for serious medical conditions. The company uses its cell therapy platform to create and manufacture specialized human cells intended to replace or support damaged cells and tissues. Its programs include OpRegen, a retinal pigment epithelial cell therapy being developed for retinal diseases; OPC1, an oligodendrocyte progenitor cell therapy for spinal cord injury; ANP1, an auditory neuron progenitor cell program for hearing loss; and VAC2, a cell-based cancer immunotherapy.
Recommended Stories
- Five stocks we like better than Lineage Cell Therapeutics
- Grand Theft Auto VI Arrives: Why Take-Two Is a Waiting Game
- Greg Abel Makes His Next Moves: Inside Berkshire’s Q3 Portfolio
- Walmart Earnings Change the Narrative as Digital Growth Lifts Outlook
- Whatever Happens to Copper Next, These 3 Investments Offer Different Ways to Play It
Receive News & Ratings for Lineage Cell Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lineage Cell Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
